+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Dysmenorrhea Treatment Market - Growth, Trends, and Forecasts (2020 - 2025)

  • ID: 5176533
  • Report
  • August 2020
  • Region: Global
  • 105 pages
  • Mordor Intelligence
until Dec 31st 2020
1 of 5

Enquire about COVID-19 updates for this product.

Enquire Now


  • Abbott Laboratories
  • Alvogen
  • Bayer AG
  • F. Hoffmann-La Roche Ltd
  • Focus Consumer Healthcare
  • GlaxoSmithKline Plc
  • MORE
The dysmenorrhea treatment market is expected to register a CAGR of 8.1% during the forecast period. Dysmenorrhea, also known as menstrual cramps, is cramping or throbbing pains in the lower abdomen. Most of the women experience dysmenorrhea just before and during their menstrual periods. Dysmenorrhea is of two types, namely primary and secondary dysmenorrhea. Prostaglandin-induced uterine contractions cause primary dysmenorrhea and secondary dysmenorrhea means pelvic pain caused by (secondary to) a disorder or disease.

Dysmenorrhea can create complications such as endometriosis that can cause fertility problems, increasing the risk of a fertilized egg implanting outside of the uterus (ectopic pregnancy), and pelvic inflammatory disease can scar fallopian tubes.

As per the study published in the International Journal of Gynecology & Obstetrics, dysmenorrhea affects more than 80% of women in the reproductive age, and it is the most common gynecological problem worldwide.

Increasing incidence and prevalence of dysmenorrhea and growing awareness regarding dysmenorrhea among females and increasing research and development by companies for developing innovative drugs are the key driving factors in the dysmenorrhea treatment market.

Key Market Trends

Non-Steroidal Anti-Inflammatory Drugs Segment is Expected to Hold a Major Market Share in the Dysmenorrhea Treatment Market

Some of the US Food and Drug Administration (FDA) approved NSAIDs for treatment of dysmenorrhea are diclofenac, ibuprofen, ketoprofen, meclofenamate, mefenamic acid, and naproxen.
  • According to the Women's Health Concern and British Menopause Society, about 80% of dysmenorrhea women experience period pain at some stage in their lifetime. Most women experience some discomfort during menstruation, especially on the first day. But in 5%-10% of women, the pain is severe enough to disrupt their life.
  • Moreover, the prevalence of diseases such as endometriosis, which is the leading cause of secondary dysmenorrhea, is also globally.
  • Non-steroidal anti-inflammatory drugs segment holds a significant market share in the dysmenorrhea treatment market. It is anticipated to show a similar trend over the forecast period due to highly effective relieving pain, lower cost, and easy availability of products.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a major market share in the global dysmenorrhea treatment market due to the increasing incidence and prevalence of dysmenorrhea and awareness of dysmenorrhea among females in this region. As per the study published in the Indian Journal of Research, in the United States, about 2 billion dollars or 600 million working hours are lost annually because of incapacitating dysmenorrhea. Moreover, women who attend classes or work have been shown to have lower work output or scores during their dysmenorrhea. Furthermore, increasing research and development for developing innovative drugs and the presence of well-established healthcare infrastructure is also fueling the growth of the overall regional market to a large extent.

Competitive Landscape

The dysmenorrhea treatment market is competitive and consists of several major players. Some of the major players include Novartis AG, Bayer AG, Abbott Laboratories, F. Hoffmann-La Roche Ltd, Sanofi, Pfizer, Inc, GlaxoSmithKline Plc, Focus Consumer Healthcare, Johnson & Johnson, and Alvogen, among others.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
Note: Product cover images may vary from those shown
2 of 5


  • Abbott Laboratories
  • Alvogen
  • Bayer AG
  • F. Hoffmann-La Roche Ltd
  • Focus Consumer Healthcare
  • GlaxoSmithKline Plc
  • MORE
1.1 Study Assumptions
1.2 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Increase In Number ff Women With Dysmenorrhea
4.2.2 Increasing Research and Development for Developing Innovative Drugs
4.3 Market Restraints
4.3.1 Side Effects and Complications Associated with Long Term Treatment
4.3.2 Lack of Awareness About Reproductive Health In Women
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Treatment Type
5.1.1 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
5.1.2 Hormonal Therapy
5.2 By Type
5.2.1 Primary Dysmenorrhea
5.2.2 Secondary Dysmenorrhea
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle East & Africa GCC South Africa Rest of Middle East & Africa
5.3.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Novartis AG
6.1.2 Bayer AG
6.1.3 Abbott Laboratories
6.1.4 F. Hoffmann-La Roche Ltd
6.1.5 Sanofi
6.1.6 Pfizer Inc
6.1.7 GlaxoSmithKline Plc
6.1.8 Focus Consumer Healthcare
6.1.9 Johnson & Johnson
6.1.10 Alvogen

Note: Product cover images may vary from those shown
3 of 5


4 of 5
  • Novartis AG
  • Bayer AG
  • Abbott Laboratories
  • F. Hoffmann-La Roche Ltd
  • Sanofi
  • Pfizer Inc
  • GlaxoSmithKline Plc
  • Focus Consumer Healthcare
  • Johnson & Johnson
  • Alvogen
Note: Product cover images may vary from those shown
5 of 5